Thin and ultra-fast photodetector sees the full spectrum

IMAGE

IMAGE: Close-up photo of the photodetectors.
view more 

Credit: RMIT University

Researchers have developed the world’s first photodetector that can see all shades of light, in a prototype device that radically shrinks one of the most fundamental elements of modern technology.

Photodetectors work by converting information carried by light into an electrical signal and are used in a wide range of technologies, from gaming consoles to fibre optic communication, medical imaging and motion detectors.
Currently photodetectors are unable to sense more than one colour in the one device.

This means they have remained bigger and slower than other technologies, like the silicon chip, that they integrate with.

The new hyper-efficient broadband photodetector developed by researchers at RMIT University is at least 1,000 times thinner than the smallest commercially available photodetector device.

In a significant leap for the technology, the prototype device can also see all shades of light between

Read More

New Data Show Genentech’s Enspryng Significantly Reduces Severity and Risk of Relapse in Neuromyelitis Optica Spectrum Disorder

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), will present new Enspryng (satralizumab-mwge) data on reducing relapse severity in the treatment of neuromyelitis optica spectrum disorder (NMOSD), a rare disease of the central nervous system. These data are being presented at MSVirtual2020, the 8th Joint Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) – European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Meeting, in addition to longer-term efficacy data supporting the continued effect of Enspryng on reducing the risk of NMOSD relapse, as well as its favorable benefit:risk profile.

“The data for Enspryng at MSVirtual2020 are promising and suggest it significantly reduces relapse severity and frequency, which are important goals of the treatment for people with NMOSD,” said Anthony Traboulsee, M.D., neurologist and professor, University of British Columbia, and Research Chair of the MS

Read More

New data show Roche’s ENSPRYNG (satralizumab) significantly reduces severity and risk of relapse in neuromyelitis optica spectrum disorder (NMOSD)

  • ENSPRYNG lowered relapse severity in double-blind periods of SAkura Phase III studies.

  • Pooled data from SAkura open-label extension (OLE) studies support continued effect of ENSPRYNG reducing risk of relapse in the longer term

  • Ongoing data continues to show a favourable safety profile for ENSPRYNG

  • ENSPRYNG was recently approved by the U.S. Food and Drug Administration (FDA) for adults with anti-aquaporin-4 (AQP4) antibody positive NMOSD

Basel, 10 September 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) will present new ENSPRYNG® (satralizumab) data on reducing relapse severity in the treatment of neuromyelitis optica spectrum disorder (NMOSD), a rare disease of the central nervous system. These data are being presented at MSVirtual2020, the 8th joint ACTRIMS-ECTRIMS meeting, in addition to longer-term efficacy data supporting the continued effect of ENSPRYNG on reducing the risk of NMOSD relapse, as well as its favourable benefit:risk profile.

“The data for ENSPRYNG at MSVirtual2020 are promising and

Read More